|1.||Schmelz, Eva M: 8 articles (10/2014 - 10/2005)|
|2.||Roberts, Paul C: 8 articles (10/2014 - 10/2005)|
|3.||Szymczak, Wiesław: 3 articles (01/2006 - 01/2004)|
|4.||Synder, Marek: 3 articles (01/2006 - 01/2004)|
|5.||Grzegorzewski, Andrzej: 3 articles (01/2006 - 01/2004)|
|6.||Vanderhyden, Barbara C: 2 articles (12/2015 - 12/2006)|
|7.||Garson, Kenneth: 2 articles (12/2015 - 12/2006)|
|8.||Yao, De-Sheng: 2 articles (12/2015 - 12/2006)|
|9.||Anderson, Angela S: 2 articles (10/2014 - 06/2013)|
|10.||Hulver, Matthew W: 2 articles (10/2014 - 06/2013)|
|2.||Ovarian Neoplasms (Ovarian Cancer)
01/01/2012 - "In this study, we investigated changes in the viscoelasticity of mouse ovarian surface epithelial (MOSE) cells, a mouse model for progressive ovarian cancer. "
01/01/2011 - "Thus, our MOSE-derived cell model represents a unique model for in depth mechanistic studies of ovarian cancer progression."
03/01/2006 - "Taken together, our findings support the utility of MOSE cells in studying ovarian cancer biology and as a source of novel diagnostic and therapeutic targets."
10/01/2005 - "Thus, our MOSE model provides an excellent tool to identify both cellular and molecular changes in the early and late stages of ovarian cancer, to evaluate their regulation, and to determine their significance in an immunocompetent in vivo environment."
10/01/2005 - "Taking advantage of the spontaneous transformation of mouse ovarian surface epithelial (MOSE) cells in culture, we isolated and characterized distinct transitional stages of ovarian cancer as the cells progressed from a premalignant nontumorigenic phenotype to a highly aggressive malignant phenotype. "
06/10/2013 - "We used our recently developed and characterized mouse ovarian surface epithelial (MOSE) cancer progression model to study metabolic changes in distinct disease stages. "
12/01/2015 - "In RM cells (mOSE transformed by K-RAS and c-MYC), PAX2 expression inhibited p53 and induced pERK1/2 and COX2, resulting in enhanced angiogenesis and decreased apoptosis of tumors arising from these cells. "
10/01/2015 - "A similar p53 mutation in murine ovarian surface epithelium (MOSE), another potential progenitor cell for serous cancer, was not sufficient to transform the cells nor change migration suggesting tissue specific effects of p53 mutation. "
09/10/2013 - "These results suggest that DAXX may transform mOSE cells to an ovarian oncogenic phenotype and may be an anti-cancer target. "
12/01/2006 - "Tumors were not observed in animals injected with either MOSE-Myc or MOSE cells. "
01/01/2006 - "Both clinical and radiological parameters (taken during fragmentation stage) were included in our study: gender, age at the onset, hip joint abduction, type of treatment, extend of the femoral head necrosis according to the Herring and Catterall classification, LLD, premature growth plate arrest, ATD and ATD index, lateral acetabulum shape - type I - normal, concave lateral acetabulum margin, type II--flat, horizontal and type III--convex, sloping, femoral head subluxation, femoral head sphericity disturbance according to the Mose, risk factors according to the Catterall, Wiberg angle, Eyre-Brook index. "
01/01/2004 - "Necrosis of the femoral head was classified according to Herring and Catterall, late results according to Stulberg and Mose and leg length discrepancy on scanograms. "
10/15/2014 - "In the present study, we compared the metabolic phenotype of the stem cell enriched cell variant, MOSE-LFFLv (TIC), derived from mouse ovarian surface epithelial (MOSE) cells, to their parental (MOSE-L) and benign precursor (MOSE-E) cells. "
10/15/2014 - "TICs have an increased survival rate under limiting conditions as well as an increased survival rate when treated with AICAR, but exhibit a higher sensitivity to metformin than MOSE-E and MOSE-L cells. "
10/15/2014 - "In contrast to MOSE-L cells, TICs can increase their rate of glycolysis to overcome the inhibition of ATP synthase by oligomycin and can increase their oxygen consumption rate to maintain proton motive force when uncoupled, similar to the benign MOSE-E cells. "
|1.||Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)
|2.||Complementary DNA (cDNA)
|7.||Adenosine Triphosphate (ATP)
|8.||Ovarian epithelial cancer
|10.||4- cyclohexyl- 1- (1,2- diphenylethyl)piperazine (cdep)
|1.||Heterologous Transplantation (Xenotransplantation)
|3.||Sodium-Restricted Diet (Diet, Sodium Restricted)